AR020019A1 - Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama - Google Patents

Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama

Info

Publication number
AR020019A1
AR020019A1 ARP990106215A ARP990106215A AR020019A1 AR 020019 A1 AR020019 A1 AR 020019A1 AR P990106215 A ARP990106215 A AR P990106215A AR P990106215 A ARP990106215 A AR P990106215A AR 020019 A1 AR020019 A1 AR 020019A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
pharmaceutical composition
breast cancer
mammals
Prior art date
Application number
ARP990106215A
Other languages
English (en)
Original Assignee
Ecosmart Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecosmart Technologies Inc filed Critical Ecosmart Technologies Inc
Publication of AR020019A1 publication Critical patent/AR020019A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas que contienen aceites esenciales de plantas, naturales o sintéticos, o mezclas o derivados de los mismos, para la prevencion yel tratamiento de cáncer de tejido blando en mamíferos.
ARP990106215A 1998-12-07 1999-12-07 Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama AR020019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11127198P 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
AR020019A1 true AR020019A1 (es) 2002-03-27

Family

ID=22337523

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106216A AR020020A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
ARP990106215A AR020019A1 (es) 1998-12-07 1999-12-07 Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
ARP990106217A AR020021A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990106216A AR020020A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990106217A AR020021A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal

Country Status (24)

Country Link
US (8) US20030017215A1 (es)
EP (3) EP1137425A1 (es)
JP (3) JP2002531511A (es)
KR (1) KR20010080692A (es)
CN (1) CN100448454C (es)
AR (3) AR020020A1 (es)
AT (1) ATE307601T1 (es)
AU (3) AU1841900A (es)
BR (1) BR9916879A (es)
CA (3) CA2353475A1 (es)
CZ (1) CZ20011979A3 (es)
DE (1) DE69928000T2 (es)
ES (1) ES2247858T3 (es)
HU (1) HUP0104674A3 (es)
ID (1) ID29393A (es)
IL (1) IL143488A0 (es)
MX (3) MXPA01005641A (es)
NO (1) NO20012774L (es)
NZ (1) NZ527850A (es)
PL (1) PL349028A1 (es)
RU (1) RU2252772C2 (es)
TR (1) TR200101481T2 (es)
WO (3) WO2000033857A1 (es)
ZA (1) ZA200104611B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017215A1 (en) * 1998-12-07 2003-01-23 Steven M. Bessette Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
DE10113513A1 (de) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040091558A1 (en) * 2002-08-12 2004-05-13 Lonza, Inc. Antimicrobial compositions
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
DE10259619A1 (de) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
MD2231C2 (ro) * 2003-03-05 2004-02-29 Ион КАЛМЫК Compozitie pentru tratamentul patologiilor oncologice
WO2004100971A1 (en) 2003-04-24 2004-11-25 Vanderbilt University Compositions and methods for controlling insects
US20060263403A1 (en) * 2003-04-24 2006-11-23 Essam Enan Compositions and methods for controlling insects involving the tyramine receptor
US7622269B2 (en) 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
CA2530884C (en) 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
DE10341933A1 (de) * 2003-09-11 2005-04-14 Lts Lohmann Therapie-Systeme Ag Medizinische Hautpflaster mit einem Gehalt an ätherischen Ölen zur Behandlung von Erkältungskrankheiten, sowie Verfahren für deren Herstellung
SE0401302D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of erk-phosphorylation
WO2006120495A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
US20090035403A2 (en) * 2005-06-16 2009-02-05 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
CN100553628C (zh) * 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
US20080145462A1 (en) * 2006-06-27 2008-06-19 Essam Enan Compositions and methods for treating parasitic infections
CN101489377A (zh) * 2006-07-17 2009-07-22 蒂拉德克公司 防治昆虫的组合物和方法
JP5587610B2 (ja) * 2007-01-16 2014-09-10 タイラテック， インク． 有害生物駆除組成物及び方法
JP2011021013A (ja) * 2009-06-19 2011-02-03 Ube Industries Ltd オキシル基を有する芳香族メチルアルコール化合物の製造方法
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
US8003393B1 (en) * 2010-02-09 2011-08-23 Panasonic Corporation Method for determining whether or not a mammal is affected with a lung cancer
WO2012006563A2 (en) 2010-07-08 2012-01-12 The Administrators Of The Tulane Educational Fund Novel daidzein analogs as treatment for cancer
FR2967055B1 (fr) * 2010-11-08 2012-12-21 Biochimie Appliquee Solabia Compositions cosmetiques a base d'esters de piperonyle et leur utilisation en sosmetique en tant qu'anti-vieillissement cutane et agent depigmentant
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
WO2012104571A1 (en) * 2011-02-02 2012-08-09 GILHOLM, Stephen, Philip Compositions of monoterpenoids for the treatment of influenza
WO2012177799A1 (en) * 2011-06-20 2012-12-27 Atheronova Operations, Inc. Subcutaneous fat reduction
EP2773315B1 (en) 2011-11-03 2015-07-08 Unilever N.V. A personal cleaning composition
KR101357395B1 (ko) 2012-08-06 2014-02-05 영남대학교 산학협력단 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
WO2015102448A1 (ko) * 2014-01-03 2015-07-09 전북대학교 산학협력단 신남알데히드 및 퀴논 메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
KR101688887B1 (ko) * 2014-01-03 2016-12-23 전북대학교산학협력단 신남알데히드 및 퀴논 메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
US20160339058A1 (en) * 2014-03-20 2016-11-24 Nestec S.A. Methods and compositions for using cinnamaldehyde and zinc for weight management
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
DE202015106125U1 (de) * 2015-10-23 2016-10-27 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige Zusammensetzung zur Behandlung von Tumor- und/oder Krebserkrankungen
CN105294465A (zh) * 2015-12-08 2016-02-03 天津医科大学 一种抗乳腺癌转移作用的手性紫罗兰酮生物碱衍生物及医药用途
CN105559074B (zh) * 2016-02-03 2019-02-12 华南农业大学 一种茶叶挥发性精油在制备防癌保健品或抗癌药物中的应用
KR101798203B1 (ko) * 2016-09-23 2017-11-15 전북대학교 산학협력단 산성 pH 및 에스테라아제에 의해 신남알데히드 및 퀴논메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
WO2019194756A1 (en) 2018-04-06 2019-10-10 Ucar Dilek Treatment of cancer by guanidinium derivatives
CN109112106B (zh) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 人原代肝癌组织的体外模型的建立方法
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022069013A1 (fr) * 2020-10-04 2022-04-07 Omar Bencherguia Composition médicamenteuse pour le traitement et la prévention du covid-19 et autres infections et affections nouvelles applications de l'alpha-acetoxytoluène, l'alcool benzylique et les groupes benzyle dans la lutte contre la pandémie covid-19 et autres infections et affections
CN119488512A (zh) * 2024-12-18 2025-02-21 澳门大学 肉桂醇及其衍生物在制备预防或治疗肿瘤的药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS57106697A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
FR2557452B1 (fr) * 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
DE3515253C1 (de) * 1985-04-27 1986-06-19 Werner 6780 Pirmasens Walter Verwendung von isopropanolischen Lösungen von Diphenyl als topisches Arzneimittel
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3829200A1 (de) * 1988-08-29 1990-03-01 Kaempgen Dieter Dr Phil Wirkstoffe gegen die immunschwaeche-krankheit aids
JP2746453B2 (ja) * 1990-03-13 1998-05-06 鐘紡株式会社 活性酸素消去剤
EP0650723A3 (en) 1990-03-23 1995-08-30 Nippon Kayaku Kk New pharmaceutical uses of forskolin derivatives.
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
FR2683454B1 (fr) 1991-11-13 1995-06-09 Pf Medicament Composition pharmaceutique bactericide.
WO1993011775A1 (en) * 1991-12-13 1993-06-24 G.D. Searle & Co. Transdermal azidothymidine
EP0567948B1 (en) * 1992-04-29 1996-09-11 NORDICA S.p.A Braking device on a roller skate
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
FR2697133B1 (fr) * 1992-10-28 1995-01-13 Transbiotech Composition biocide et/ou biostatique et ses applications.
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
JP3263481B2 (ja) 1993-05-19 2002-03-04 三洋電機株式会社 半導体装置および半導体装置の製造方法
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
RU2088245C1 (ru) * 1993-07-07 1997-08-27 Научно-исследовательский институт онкологии им.проф.Н.Н.Петрова Способ профилактики повышенного онкологического риска
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RU2102947C1 (ru) * 1994-01-12 1998-01-27 Любовь Сергеевна Кондаурова Средство для лечения заболеваний переднего отрезка глаза
RU2088247C1 (ru) * 1994-01-31 1997-08-27 Фонд содействия исследованиям и инициативам граждан по оздоровлению человека и среды им.Караваева В.В. Способ повышения эффективности лучевой терапии
US5626854A (en) 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
PL335506A1 (en) * 1997-03-04 2000-04-25 Wisconsin Alumni Res Found Method of inhibiting neoplasm growth by means of combinations of isoprenoids and statins
AU7165798A (en) 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
WO1999003498A1 (en) * 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
BR9815747A (pt) * 1998-03-20 2000-11-14 Procter & Gamble Composição para liberação de aroma
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
WO2000024409A1 (de) * 1998-10-23 2000-05-04 Dieter Ebert Zusammensetzung enthaltend eugenol und polyphenole, verwendung einer solchen zusammensetzung zur wundheilung
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
US20030017215A1 (en) * 1998-12-07 2003-01-23 Steven M. Bessette Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Also Published As

Publication number Publication date
AR020020A1 (es) 2002-03-27
HUP0104674A3 (en) 2003-01-28
AU1841900A (en) 2000-06-26
WO2000033857A1 (en) 2000-06-15
JP2002531511A (ja) 2002-09-24
EP1137426B1 (en) 2005-10-26
US20030108622A1 (en) 2003-06-12
US6812258B2 (en) 2004-11-02
WO2000033858A1 (en) 2000-06-15
US20040146595A1 (en) 2004-07-29
JP2002531512A (ja) 2002-09-24
MXPA01005598A (es) 2003-07-14
US20030108623A1 (en) 2003-06-12
BR9916879A (pt) 2001-11-06
WO2000033856A1 (en) 2000-06-15
US20030017215A1 (en) 2003-01-23
EP1137425A1 (en) 2001-10-04
IL143488A0 (en) 2002-04-21
US20030017218A1 (en) 2003-01-23
CA2353516A1 (en) 2000-06-15
AU2167100A (en) 2000-06-26
ES2247858T3 (es) 2006-03-01
US20040156922A1 (en) 2004-08-12
JP2002531513A (ja) 2002-09-24
WO2000033857A9 (en) 2001-12-13
AU2167000A (en) 2000-06-26
PL349028A1 (en) 2002-07-01
CN100448454C (zh) 2009-01-07
ID29393A (id) 2001-08-30
AR020021A1 (es) 2002-03-27
NZ527850A (en) 2004-07-30
US20020182268A1 (en) 2002-12-05
ZA200104611B (en) 2001-12-13
CN1329498A (zh) 2002-01-02
DE69928000T2 (de) 2006-06-08
RU2252772C2 (ru) 2005-05-27
KR20010080692A (ko) 2001-08-22
MXPA01005545A (es) 2003-07-14
ATE307601T1 (de) 2005-11-15
HUP0104674A2 (en) 2002-06-29
CA2353475A1 (en) 2000-06-15
EP1137427A1 (en) 2001-10-04
EP1137426A1 (en) 2001-10-04
DE69928000D1 (de) 2005-12-01
CA2353476A1 (en) 2000-06-15
US7291650B2 (en) 2007-11-06
US7008649B2 (en) 2006-03-07
NO20012774D0 (no) 2001-06-06
MXPA01005641A (es) 2003-07-14
CZ20011979A3 (cs) 2001-10-17
US20080015249A1 (en) 2008-01-17
NO20012774L (no) 2001-06-06
TR200101481T2 (tr) 2001-09-21

Similar Documents

Publication Publication Date Title
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
BR0113235A (pt) Composições e métodos para a terapia e a diagnose de malignidades associadas com her-2/neu
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
SE9802937D0 (sv) Novel compounds
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad
ES2163634T3 (es) Benzopiranos y composiciones farmaceuticas que les contienen.
DE69815100D1 (de) Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
MX9300406A (es) Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen.
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
AR021463A1 (es) Antibiotico de piridona con perfil de seguridad mejorado
AR023644A1 (es) 3-aril-pirazoles substituidos, procedimiento para su obtencion, procedimiento para la lucha contra plantas indeseables, empleo de los mismos contra plantasindeseables y/o como fungicida, y composicion para el tratamiento de plantas

Legal Events

Date Code Title Description
FB Suspension of granting procedure